Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jun 14, 2013; 19(22): 3397-3403
Published online Jun 14, 2013. doi: 10.3748/wjg.v19.i22.3397
Published online Jun 14, 2013. doi: 10.3748/wjg.v19.i22.3397
Endoscopic ultrasound-guided ethanol ablation therapy for tumors
Wen-Ying Zhang, Zhao-Shen Li, Zhen-Dong Jin, Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Author contributions: Li ZS and Jin ZD conceived and designed the study, helped to write and edit the manuscript, and contributed equally to this work and should be considered co-corresponding authors; Zhang WY wrote the paper.
Supported by A grant from the Shanghai Science and Technology Committee Foundation, No. 11D21921605
Correspondence to: Zhen-Dong Jin, MD, Department of Gastroenterology, Changhai Hospital, Second Military Medical University, No. 168 Changhai Road, Shanghai 200433, China. zhendong_jin@126.com
Telephone: +86-21-31161336 Fax: +86-21-55621735
Received: February 9, 2013
Revised: May 14, 2013
Accepted: May 18, 2013
Published online: June 14, 2013
Revised: May 14, 2013
Accepted: May 18, 2013
Published online: June 14, 2013
Core Tip
Core tip: Ethanol, a commonly used ablative agent, has been used to successfully and safely ablate solid and cystic hepatic lesions via percutaneous injection. Endoscopic ultrasonography (EUS)-guided ethanol ablation, a minimally invasive approach, was recently developed and has been successfully applied as treatment of pancreatic cysts, pancreatic neuroendocrine tumors, and abdominal metastatic lesions. Although it is not likely to replace radical resection for treating localized lesions or systemic therapy for managing metastatic tumors, EUS-guided ablation therapies represent an attractive alternative treatment modality for patients who refuse or are not eligible for surgery.